What is the expected price of ibrutinib/ibrutinib in 2025?

Ibrutinib/Ibrutinib (Ibrutinib) is an oral small molecule drug mainly used to treat a variety of B cell-related malignant hematological tumors, such aschronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL) and Waldenstrom's macroglobulinemia. By inhibiting Bruton's tyrosine kinase (BTK), ibrutinib can effectively interfere with B cell receptor signaling and inhibit the proliferation and survival of tumor cells. BTK plays a crucial role in the development, function and immune response of B cells. Therefore, by targeting the action of this enzyme, ibrutinib can significantly improve the prognosis of patients, especially showing its therapeutic value in refractory and relapsed cases.

As the application of ibrutinib continues to expand, its global market demand is also gradually growing. In China, the original drug of ibrutinib has been launched and has been successfully included in the Class B medical insurance reimbursement system. This means that patients who meet the indications can be reimbursed by medical insurance, significantly reducing the burden of the drug. Taking 140mg 90 tablets of ibrutinib as an example, patients need to pay more than 10,000 yuan when purchasing the drug, which is already a relatively affordable amount for many patients.

However, the price of ibrutinib in overseas markets is much higher than that in China, especially in the United States. A single strength of the drug may cost more than more than 10,000 US dollars, which is undoubtedly a huge financial burden for many patients. In order to reduce the cost pressure on patients, some countries and regions have begun to launch generic drugs to provide more economical alternatives. Take the generic drug of ibrutinib produced by Bangladesh Yaopin International as an example. The price of this drug in 140 mg and 112 tablets is about more than 2,000 yuan, which is significantly lower than the original drug. Although the quality and efficacy of generic drugs are similar to those of brand-name drugs, patients still need to consult their doctors when choosing to ensure the effectiveness and safety of the treatment plan.

Reference materials:https://www.imbruvica.com/